S. Huijberts

发表

BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.

J. Desai, J. Schellens, J. Tabernero, 2018 .

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

R. Bernards, J. Schellens, H. Rosing, 2020, British Journal of Cancer.

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

Evert Bosdriesz, Jos H. Beijnen, Ji-Ying Song, 2018, Cell.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

J. Desai, E. Van Cutsem, J. Schellens, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib

R. Bernards, M. Boelens, Frans L Opdam, 2020, British journal of cancer.

Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study.

R. Bernards, J. Schellens, H. Rosing, 2020, Future oncology.

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

R. Bernards, J. Schellens, H. Rosing, 2020, Cancer Chemotherapy and Pharmacology.

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.

R. Bernards, J. Beijnen, N. Steeghs, 2020, Future oncology.

Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).

J. Desai, E. Van Cutsem, J. Schellens, 2019, Journal of Clinical Oncology.

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.

R. Bernards, J. Schellens, H. Rosing, 2020, The oncologist.

Phase I Study of Afatinib and Selumetinib in Patients with KRASâ•’Mutated Colorectal, Nonâ•’Small Cell Lung, and Pancreatic Cancer

R. Bernards, H. Rosing, J. Beijnen, 2021 .

Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.

R. Bernards, J. Schellens, H. Rosing, 2020 .

517PBEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)

J. Desai, J. Schellens, A. Grothey, 2017 .

Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study.

H. Rosing, J. Beijnen, M. Tibben, 2019, Journal of pharmaceutical and biomedical analysis.

BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer.

J. Desai, E. Van Cutsem, J. Schellens, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.